Related Experiment Video

Updated: Jan 2, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K

Immune Resistance and EGFR Antagonists in Colorectal Cancer

Guido Giordano1, Andrea Remo2, Almudena Porras3,4

  • 1U.O.C. Medical Oncology, Ospedali Riuniti, Azienda Ospedaliero Universitaria, 251 Foggia, Italy.

Cancers
|August 3, 2019
PubMed

Insights

Targeting epidermal growth factor receptor (EGFR) in metastatic colorectal cancer (mCRC) shows promise but faces resistance. Understanding resistance mechanisms and tumor microenvironment interactions is key to improving patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Epidermal growth factor receptor (EGFR) targeted therapies have transformed metastatic colorectal cancer (mCRC) treatment.
  • However, clinical outcomes are often limited by primary and acquired resistance.
  • Tumor heterogeneity and genomic instability contribute to treatment escape.

Purpose of the Study:

  • To review recent findings on resistance mechanisms to anti-EGFR therapy in mCRC.
  • To explore the role of molecular alterations and the tumor microenvironment in treatment efficacy.
  • To analyze strategies for overcoming EGFR therapy resistance.

Main Methods:

  • Literature review of recent studies on EGFR resistance in mCRC.
  • Analysis of molecular pathways and immune interactions.
  • Evaluation of therapeutic strategies targeting the tumor microenvironment.

Main Results:

  • Multiple pathways contribute to resistance against EGFR inhibitors.
  • Genomic instability and tumor microenvironment dynamics play significant roles.
  • Complex molecular alterations are linked to treatment efficacy.

Conclusions:

  • Understanding acquired resistance to EGFR therapy is crucial for improving mCRC patient outcomes.
  • Modulating the tumor microenvironment may enhance the efficacy of EGFR antagonists.
  • Further research into resistance mechanisms is needed to develop more effective treatments.
Keywords:
EGFRcolorectal cancerimmune microenvironmentresistancetargeted therapies

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.3K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.6K